News Snapshot:
The single-shot Ad5-nCoV vaccine, co-developed by CanSinoBIO with the Beijing Biotechnology Institute with the support of the Chinese Army, has been approved for use in countries such as China, Mexico and Pakistan. A 57.5% efficacy against symptomatic COVID-19 means a 57.5% reduction in the risk of symptomatic disease in vaccinated individuals compared to unvaccinated individuals, Phase III. It was obtained from an analysis of 150 cases in a cohort of more than 20,000 healthy adults in the clinic. I wrote a clinical trial and a researcher. The study, published Thursday in The Lancet Medical Journal, did not investigate how recent...
